Allergan (AGN) says Darpin data does not support Phase 3 trials.

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Allergan (AGN) says Darpin data does not support Phase 3 trials.

Lazard Capital Upgrades Allergen (AGN) to Buy

May 2, 2013 7:11 AM EDT

Lazard Capital upgraded Allergen (NYSE: AGN) from Hold to Buy.

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $98.67 yesterday, with a 52 week range of $81.28-$116.45.... More

Morgan Stanley Downgrades Allergen (AGN) to Equalweight

May 1, 2013 2:31 PM EDT

Morgan Stanley downgraded Allergen (NYSE: AGN) from Overweight to Equalweight.

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $113.55 yesterday, with a 52 week range of $81.28-$116.45.... More

Allergan (AGN) Strong With or Without DARPin - RBC

May 1, 2013 12:02 PM EDT

Analysts at RBC Capital think the market overreacted to news about Allergen's (NYSE: AGN) DARPin. Today Allergan's CEO said data on DARPin does not support Phase 3 trials, which will delay approval by 1-2 years. This sent shares lower by well over 10 percent, but RBC... More

Allergan, Inc. (AGN) trading paused for volatility

May 1, 2013 11:06 AM EDT

Allergan, Inc. (NYSE: AGN) trading paused for volatility.... More